Xenon Pharmaceuticals Inc. - 8-K Filing
Xenon Pharmaceuticals reported Q1 2026 financial results with $1.34 billion in cash, cash equivalents, and marketable securities as of March 31, 2026, up from $586.0 million in December 2025. The company incurred a net loss of $102.3 million for the quarter, compared to $65.0 million in the same period in 2025, driven by higher R&D and G&A expenses and lower collaboration revenue. The company announced positive Phase 3 X-TOLE2 trial results for azetukalner in focal onset seizures and plans to submit an NDA to the FDA in Q3 2026. (Items: 2.02 Results of Operations and Financial Condition On May 7, 2026, Xenon Pharmaceuticals Inc, 7.01 Regulation FD Disclosure The Company announces material information to the public through a variety of means, including filings with the Secu, 9.01 Financial Statements and Exhibits (d) Exhibits)
Tickers: $XENE